Next Article in Journal
Selective Inhibition of Human Monoamine Oxidase B by Acacetin 7-Methyl Ether Isolated from Turnera diffusa (Damiana)
Previous Article in Journal
The Effect of the Chemical Character of Ionic Liquids on Biomass Pre-Treatment and Posterior Enzymatic Hydrolysis
Review

The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules

1
KRISP, School of Laboratory of Medicine and Medical Science, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa
2
School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa
3
CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine, Department of Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain
*
Authors to whom correspondence should be addressed.
Academic Editor: Diego Muñoz-Torrero
Molecules 2019, 24(4), 809; https://doi.org/10.3390/molecules24040809
Received: 29 January 2019 / Revised: 21 February 2019 / Accepted: 21 February 2019 / Published: 23 February 2019
(This article belongs to the Section Medicinal Chemistry)
The Food and Drug Administration approved 59 new drugs (42 New Chemical Entities and 17 Biologics) during 2018. This number breaks the previous record of 53 approved by the same organization in 1996. The 17 new biologics approved in 2018 also represent an important milestone for this kind of drug and they clearly exceed the 12 approved in 2015 and 2017. Herein, the 59 new drugs of the class of 2018 are analyzed from a strictly chemical perspective. The classification has been carried out on the basis of the chemical structure and includes the following: Biologics (antibodies and enzymes); TIDES (peptides and oligonucleotides) and natural products; drug combinations; and small molecules. View Full-Text
Keywords: antibodies; API; biologics; chemical entities; drug discovery; fluorine based drugs; natural products; oligonucleotides; peptide; TIDES; small molecules antibodies; API; biologics; chemical entities; drug discovery; fluorine based drugs; natural products; oligonucleotides; peptide; TIDES; small molecules
Show Figures

Figure 1

MDPI and ACS Style

G. de la Torre, B.; Albericio, F. The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules 2019, 24, 809. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules24040809

AMA Style

G. de la Torre B, Albericio F. The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules. 2019; 24(4):809. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules24040809

Chicago/Turabian Style

G. de la Torre, Beatriz; Albericio, Fernando. 2019. "The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules" Molecules 24, no. 4: 809. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules24040809

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop